Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC lifted its holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) by 20.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,500 shares of the company’s stock after purchasing an additional 12,800 shares during the quarter. Renaissance Technologies LLC owned about 0.41% of Nuvectis Pharma worth $472,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NVCT. Baxter Bros Inc. acquired a new stake in Nuvectis Pharma in the second quarter worth about $79,000. Baldwin Brothers LLC MA boosted its stake in Nuvectis Pharma by 9.4% in the 2nd quarter. Baldwin Brothers LLC MA now owns 168,630 shares of the company’s stock worth $1,067,000 after purchasing an additional 14,500 shares in the last quarter. Vanguard Group Inc. grew its position in Nuvectis Pharma by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 298,800 shares of the company’s stock worth $2,450,000 after purchasing an additional 4,517 shares during the last quarter. Finally, Blue Zone Wealth Advisors LLC acquired a new position in Nuvectis Pharma during the 1st quarter valued at approximately $118,000. 96.77% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of Nuvectis Pharma in a research note on Tuesday, August 6th.

Nuvectis Pharma Stock Performance

Nuvectis Pharma stock opened at $6.19 on Friday. The business’s 50-day simple moving average is $6.55 and its two-hundred day simple moving average is $6.71. The company has a market cap of $113.62 million, a PE ratio of -4.39 and a beta of 0.46. Nuvectis Pharma, Inc. has a fifty-two week low of $5.85 and a fifty-two week high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT) last posted its earnings results on Tuesday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.26). As a group, analysts predict that Nuvectis Pharma, Inc. will post -1.05 EPS for the current fiscal year.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.